To our knowledge, this is the first report of anlotinib monotherapy (with radiotherapy) in MMNST, achieving a PFS of more than 32 monthsmarkedly longer than the typical survival for advanced disease
Retatrutide is an investigational once-weekly triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide and tirzepatide
Results from Gluta White products are not permanent if usage and lifestyle are not maintained
it also plays a significant role in fat metabolism
Originally developed for type 2 diabetes management, semaglutide has demonstrated remarkable efficacy in clinical trials for weight management in individuals without diabetes
Khanna A, English SW, Wang XS et al (2017) Angiotensin II for the treatment of vasodilatory shock